Trials / Withdrawn
WithdrawnNCT04964050
A Bioequivalence Study Between Capozide Versus ACE-Hemmer-ratiopharm in Healthy Adult Participants Under Fasting Conditions
An Open-label, Randomized Three Period, Three Sequence, Partially Replicated Crossover Bioequivalence Study of Two Oral Formulations of Captopril/Hydrochlorothiazide 50/25 mg Tablets in Healthy Adult Participants Under Fasting Conditions
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is a bioequivalence study to compare Capozide (test product \[T\]) to ACE-Hemmer-ratiopharm (reference product\[R\]) produced by Ratiopharm GmbH Germany in healthy adult participants under fasting conditions. ACE-Hemmer-ratiopharm®is the registered trademark of Ratiopharm GmbH Germany.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capozide | Capozide will be administered as per the treatment sequence. |
| DRUG | ACE-Hemmer-Ratiopharm | ACE-Hemmer-Ratiopharm will be administered as per the treatment sequence. |
Timeline
- Start date
- 2022-04-21
- Primary completion
- 2022-05-26
- Completion
- 2022-05-26
- First posted
- 2021-07-15
- Last updated
- 2023-01-27
Source: ClinicalTrials.gov record NCT04964050. Inclusion in this directory is not an endorsement.